Dateline City:
WHITEHOUSE STATION, N.J.
Company to Initiate Phase 3 Clinical Development Program in Q2 2014
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new Phase 2 data for its two investigational
hepatitis C virus (HCV) treatments - MK-5172, an investigational HCV
NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A
replication complex inhibitor are scheduled to be presented at the 49th
Annual Meeting of the European Association for the Study of the Liver
(EASL), also known as The International Liver Congress 2014.
Language:
English
Contact:
MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more